RedHill Biopharma (RDHL) Intangibles (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Intangibles data on file, last reported at $5.3 million in Q4 2025.

• On a quarterly basis, Intangibles fell 4.62% year-over-year to $5.3 million in Q4 2025; TTM through Dec 2025 was $5.3 million, a 4.62% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 4.62% from the prior year.
• Intangibles for Q4 2025 stood at $5.3 million, down from $5.5 million in the prior quarter.
• Over the last five years, Intangibles for RDHL reached as high as $86.1 million in Q1 2021 and fell as low as -$29.4 million in Q4 2022.
• Historically, Intangibles has averaged $30.8 million across 5 years, with a median of $5.6 million in 2023.
• Across the five-year window, Intangibles plunged 25206.9% in 2022 and jumped 3198.88% in 2024, its largest moves.
• Year by year, Intangibles stood at -$116000.0 in 2021, then plunged by 25206.9% to -$29.4 million in 2022, then surged by 99.39% to -$179000.0 in 2023, then soared by 3198.88% to $5.5 million in 2024, then declined by 4.62% to $5.3 million in 2025.
• Per Business Quant data, the three most recent Intangibles figures were $5.3 million in Q4 2025, $5.5 million in Q2 2025, and $5.5 million in Q4 2024.